Skip to main content
ENZN
OTC Life Sciences

Enzon Finalizes Terms for Merger with Viskase, Confirming 1-for-100 Reverse Split and Significant Dilution

Analisis de IA por Wiseek
Sentimiento info
Negativo
Importancia info
9
Precio
$0.079
Cap. de mercado
$5.856M
Min. 52 sem.
$0.031
Max. 52 sem.
$0.186
Market data snapshot near publication time

summarizeResumen

This definitive prospectus (424B3) finalizes the terms of the previously announced merger with Viskase, confirming a highly dilutive outcome for existing Enzon common stockholders. The transaction involves a 1-for-100 reverse stock split and an exchange of Series C Preferred Stock for common stock, leading to legacy Enzon common stockholders retaining only about 5% ownership in the newly formed "Viskase Holdings, Inc." This represents a significant loss of equity and voting power. Furthermore, the merger consolidates control under Icahn Enterprises Holdings L.P. (IEH Parties), who will own approximately 93.32% of the combined company. While the merger provides a solution to Viskase's stated "substantial doubt" about its ability to continue as a going concern, the terms are overwhelmingly unfavorable for non-IEH Enzon shareholders, fundamentally altering their investment thesis. Investors should be aware of the drastic change in ownership structure and control.


check_boxEventos clave

  • Merger Finalized

    Enzon will merge with Viskase, with Viskase becoming a wholly-owned subsidiary. The combined entity will be renamed "Viskase Holdings, Inc." and its common stock will be quoted on OTCQB.

  • Significant Dilution for Existing Shareholders

    Legacy Enzon common stockholders are expected to own approximately 5% of the combined company's common stock post-merger, representing a substantial reduction in their equity and voting power.

  • Reverse Stock Split Confirmed

    A 1-for-100 reverse stock split will be effected immediately prior to the merger, reducing the number of outstanding common shares.

  • Preferred Stock Exchange Offer

    Enzon will offer to exchange its Series C Preferred Stock for common stock, with the IEH Parties converting their 98.2% stake and other holders offered the same terms, based on the adjusted volume-weighted average price of $7.83 per share.


auto_awesomeAnalisis

This definitive prospectus (424B3) finalizes the terms of the previously announced merger with Viskase, confirming a highly dilutive outcome for existing Enzon common stockholders. The transaction involves a 1-for-100 reverse stock split and an exchange of Series C Preferred Stock for common stock, leading to legacy Enzon common stockholders retaining only about 5% ownership in the newly formed "Viskase Holdings, Inc." This represents a significant loss of equity and voting power. Furthermore, the merger consolidates control under Icahn Enterprises Holdings L.P. (IEH Parties), who will own approximately 93.32% of the combined company. While the merger provides a solution to Viskase's stated "substantial doubt" about its ability to continue as a going concern, the terms are overwhelmingly unfavorable for non-IEH Enzon shareholders, fundamentally altering their investment thesis. Investors should be aware of the drastic change in ownership structure and control.

En el momento de esta presentación, ENZN cotizaba a 0,08 $ en OTC dentro del sector Life Sciences, con una capitalización de mercado de aproximadamente 5,9 M$. El rango de cotización de 52 semanas fue de 0,03 $ a 0,19 $. Este documento fue evaluado con un sentimiento de mercado negativo y una puntuación de importancia de 9 sobre 10.

descriptionVer presentacion principal de la SEC

show_chartGrafico de precios

Compartir este articulo

Copied!

feed ENZN - Ultimos analisis

ENZN
Mar 27, 2026, 7:48 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
ENZN
Mar 26, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
9
ENZN
Mar 25, 2026, 8:38 AM EDT
Filing Type: 425
Importance Score:
7
ENZN
Mar 25, 2026, 8:36 AM EDT
Filing Type: 8-K
Importance Score:
7
ENZN
Mar 24, 2026, 8:35 AM EDT
Filing Type: SC TO-I/A
Importance Score:
8
ENZN
Mar 24, 2026, 8:30 AM EDT
Filing Type: 425
Importance Score:
8
ENZN
Mar 24, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
ENZN
Mar 19, 2026, 4:07 PM EDT
Filing Type: SC TO-I/A
Importance Score:
7
ENZN
Mar 16, 2026, 4:10 PM EDT
Filing Type: 425
Importance Score:
7
ENZN
Mar 11, 2026, 8:36 AM EDT
Filing Type: 425
Importance Score:
7